Severe, Prolonged, Denosumab-Induced Hypocalcemia With Recovery After 111 Days Of High-Dose Calcium Supplementation
| Autor: | Jill T. Johnson, Rachael McCaleb |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry 030209 endocrinology & metabolism Case Reports General Medicine RC648-665 Monoclonal antibody Gastroenterology Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences 0302 clinical medicine Calcium supplementation Denosumab 030220 oncology & carcinogenesis Internal medicine medicine In patient business medicine.drug |
| Zdroj: | AACE Clinical Case Reports, Vol 5, Iss 1, Pp e82-e85 (2019) |
| ISSN: | 2376-0605 |
| Popis: | Objective: Denosumab is a monoclonal antibody commonly used for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Hypocalcemia is a known adverse effect with denosumab, and we present an unusual case where 2 hypocalcemic events occurred after 1 denosumab treatment.Methods: A 76-year-old man recently diagnosed with prostate cancer with bone metastasis was given 120 mg denosumab subcutaneously due to extensive bone disease.Results: The patient experienced denosumab-induced hypocalcemia induced by a single denosumab dose which was resolved after 14 days of multiple doses of intravenous calcium gluconate and oral calcium and vitamin D replacement. However, the patient returned with acute kidney injury and severe hypocalcemia (corrected calcium of 6.9 mg/dL) without any additional dose of denosumab. The recovery following the second episode of hypocalcemia was much longer than the initial episode in this patient.Conclusion: To our knowledge, this is the first reported case of an additional episode of hypocalcemia following a single denosumab dose. This case highlights the importance of close monitoring of renal function and serum electrolytes following the resolution of denosumab-induced hypocalcemia.Abbreviations: 25(OH)D = 25-hydroxyvitamin D; AKI = acute kidney injury; CI = confidence interval; IV = intravenous; PTH = parathyroid hormone; SRE = skeletal-related event; ZA = zoledronic acid |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|